{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T04:19:43Z","timestamp":1775708383641,"version":"3.50.1"},"reference-count":8,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2004,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The bactericidal activity of moxifloxacin alone and in combination with cefepime or piperacillin-tazobactam against clinical isolates of\n            <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n            ,\n            <jats:italic>Enterobacter cloacae<\/jats:italic>\n            , and\n            <jats:italic>Acinetobacter baumannii<\/jats:italic>\n            was evaluated by using time-kill methods and antimicrobial concentrations of one-half and one times the MIC. Synergy was observed in 58 to 88% of the strains and resulted in bactericidal activity against 60 to 100% of the strains. Combinations including moxifloxacin demonstrated enhanced bactericidal activity compared with that of either agent tested alone.\n          <\/jats:p>","DOI":"10.1128\/aac.48.3.1055-1057.2004","type":"journal-article","created":{"date-parts":[[2004,2,24]],"date-time":"2004-02-24T17:53:08Z","timestamp":1077645188000},"page":"1055-1057","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Synergistic Activities of Moxifloxacin Combined with Piperacillin-Tazobactam or Cefepime against\n            <i>Klebsiella pneumoniae<\/i>\n            ,\n            <i>Enterobacter cloacae<\/i>\n            , and\n            <i>Acinetobacter baumannii<\/i>\n            Clinical Isolates"],"prefix":"10.1128","volume":"48","author":[{"given":"Rose","family":"Jung","sequence":"first","affiliation":[{"name":"Antimicrobial Research Laboratory, Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maroof","family":"Husain","sequence":"additional","affiliation":[{"name":"Antimicrobial Research Laboratory, Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael K.","family":"Choi","sequence":"additional","affiliation":[{"name":"Antimicrobial Research Laboratory, Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas N.","family":"Fish","sequence":"additional","affiliation":[{"name":"Antimicrobial Research Laboratory, Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-6553(99)70031-3"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199957030-00007"},{"key":"e_1_3_2_4_2","unstructured":"Bayer Corporation. 2001. Avelox and Avelox I.V. (moxifloxacin) prescribing information. Bayer Corporation West Haven Conn."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.9.2.148"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.8.1818"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.115.2.462"},{"key":"e_1_3_2_8_2","unstructured":"National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_9_2","unstructured":"National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26-A. National Committee for Clinical Laboratory Standards Wayne Pa."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.3.1055-1057.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.3.1055-1057.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:19:39Z","timestamp":1645467579000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.48.3.1055-1057.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["10.1128\/AAC.48.3.1055-1057.2004"],"URL":"https:\/\/doi.org\/10.1128\/aac.48.3.1055-1057.2004","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3]]},"assertion":[{"value":"2003-04-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-12-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}